TG Therapeutics Inc. (NASDAQ:TGTX) shares rose 5.2% during mid-day trading on Wednesday . The stock traded as high as $6.03 and last traded at $6.02, with a volume of 308,334 shares. The stock had previously closed at $5.72.

TGTX has been the topic of several analyst reports. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research note on Thursday, April 14th. Zacks Investment Research downgraded shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 14th. SunTrust Banks Inc. initiated coverage on shares of TG Therapeutics in a research note on Friday, May 27th. They issued a “buy” rating and a $18.00 target price on the stock. Brean Capital reiterated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, May 31st. Finally, Roth Capital reiterated a “buy” rating and issued a $33.00 target price on shares of TG Therapeutics in a research note on Thursday, June 9th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $22.33.

The firm’s 50-day moving average price is $6.19 and its 200 day moving average price is $7.95. The company’s market cap is $328.25 million.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. Analysts expect that TG Therapeutics Inc. will post ($1.15) EPS for the current year.

A hedge fund recently raised its stake in TG Therapeutics stock. New York State Common Retirement Fund raised its position in shares of TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent quarter.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.